RecruitingRecruiting
Pentoxifylline in Patients With Ulcerative Colitis
NCT07349472 · Tanta University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis
About this study
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Eligibility criteria
Inclusion Criteria:
* Age ≥ 18 years
* Both male and female will be included
* Negative pregnancy test and effective contraception.
* Mild and moderate UC patients
Exclusion Criteria:
* Breast feeding
* Significant liver and kidney function abnormalities
* Diabetic patients
* Colorectal cancer patients
* Patients with severe UC
* Patients taking rectal or systemic steroids
* Patients taking immunosuppressives or biological therapies
* Addiction to alcohol and / or drugs
* Known allergy to the studied medications
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-01-20
Estimated completion: 2027-02-20
Last updated: 2026-04-15
Interventions
Drug: MesalamineDrug: Pentoxifylline
Primary outcomes
- • Change in partial Mayo score (6 months)
Sponsor
Ihab Elsayed Hassan · other
All locations (1)
Fayoum UniversityRecruiting
Al Fayyum, Egypt